Top Suppliers:I want be here


2244992-76-3

2244992-76-3 structure
2244992-76-3 structure
  • Name: CHMFL-PI3KD-317
  • Chemical Name: CHMFL-PI3KD-317
  • CAS Number: 2244992-76-3
  • Molecular Formula: C21H24ClN5O3S2
  • Molecular Weight: 494.03
  • Catalog: Signaling Pathways PI3K/Akt/mTOR PI3K
  • Create Date: 2019-03-03 14:34:59
  • Modify Date: 2024-01-13 17:33:41
  • CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50s of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, 62.6 nM), PI3Kβ (IC50, 284 nM), PI3Kγ (IC50, 202.7 nM), PIK3C2A (IC50, >10000 nM), PIK3C2B (IC50, 882.3 nM), VPS34 (IC50, 1801.7 nM), PI4KIIIA (IC50, 574.1 nM) and PI4KIIIB (IC50, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC50 of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells[1].

Name CHMFL-PI3KD-317
Synonyms MFCD31813683
Description CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50s of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, 62.6 nM), PI3Kβ (IC50, 284 nM), PI3Kγ (IC50, 202.7 nM), PIK3C2A (IC50, >10000 nM), PIK3C2B (IC50, 882.3 nM), VPS34 (IC50, 1801.7 nM), PI4KIIIA (IC50, 574.1 nM) and PI4KIIIB (IC50, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC50 of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells[1].
Related Catalog
Target

PI3Kδ:6 nM (IC50)

PI3Kα:62.6 nM (IC50)

PI3Kβ:284 nM (IC50)

PI3Kγ:202.7 nM (IC50)

PIK3C2B:882.3 nM (IC50)

Vps34:1801.7 nM (IC50)

PI4KIIIA:574.1 nM (IC50)

PI4KIIIB:300.2 nM (IC50)

In Vitro CHMFL-PI3KD-317 (Compound 15i) is a highly potent and selective PI3Kδ inhibitor, with an IC50s of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, 62.6 nM), PI3Kβ (IC50, 284 nM), PI3Kγ (IC50, 202.7 nM), PIK3C2A (IC50, >10000 nM), PIK3C2B (IC50, 882.3 nM), VPS34 (IC50, 1801.7 nM), PI4KIIIA (IC50, 574.1 nM) and PI4KIIIB (IC50, 300.2 nM)[1]. In cellular assay, CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC50 of 4.3 nM[1]. CHMFL-PI3KD-317 has antiproliferative effects, with GI50s of 3.5 ± 0.8, 4.0 ± 0.9, 4.8 ± 0.2, 3.3 ± 0.2, 3.0 ± 0.4 μM against PF382, NALM-6, MV4-11, MOLM-14 and MOLM-13 cells, respectively[1].
In Vivo CHMFL-PI3KD-317 (Compound 15i) shows favorable oral bioavailability and acceptable half-life (T1/2 = 3.28 h) in Sprague-Dawley rats[1]. CHMFL-PI3KD-317 (25, 50 and 100 mg/kg/day, p.o.) inhibits the growth of the MOLM14 tumor in mice[1].
References

[1]. Liang X, et al. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. Eur J Med Chem. 2018 Aug 5;156:831-846.

Molecular Formula C21H24ClN5O3S2
Molecular Weight 494.03
Storage condition -20°C